PE20120990A1 - Formulaciones de alisquireno e hidroclorotiazida - Google Patents

Formulaciones de alisquireno e hidroclorotiazida

Info

Publication number
PE20120990A1
PE20120990A1 PE2012000368A PE2012000368A PE20120990A1 PE 20120990 A1 PE20120990 A1 PE 20120990A1 PE 2012000368 A PE2012000368 A PE 2012000368A PE 2012000368 A PE2012000368 A PE 2012000368A PE 20120990 A1 PE20120990 A1 PE 20120990A1
Authority
PE
Peru
Prior art keywords
hydrochlorothiazide
weight
alisquirene
formulations
dosage form
Prior art date
Application number
PE2012000368A
Other languages
English (en)
Inventor
Matthias Willmann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36803824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120990(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20120990A1 publication Critical patent/PE20120990A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A UNA FORMA DE DOSIFICACION SOLIDA QUE COMPRENDE: a) DE 25% A 47% EN PESO DE ALISQUIRENO, b) 0,5% A 10% EN PESO DE HIDROCLOROTIAZIDA (HCTZ) Y c) 3% A 30% EN PESO DE UN RELLENO HIDROFILICO COMPRENDIDO DE UNA MEZCLA DE ALMIDON DE TRIGO Y LACTOSA. LA COMPOSICION TAMBIEN COMPRENDE UN RELLENO ADICIONAL, UN DESINTEGRANTE TAL COMO PVP RETICULADA, UN LUBRICANTE, UN DESLIZANTE, UN AGLUTINANTE. DICHA FORMA DE DOSIFICACION ORAL SE ENCUENTRA BAJO LA FORMA DE TABLETA O TABLETA RECUBIERTA POR UNA PELICULA
PE2012000368A 2006-06-23 2007-06-22 Formulaciones de alisquireno e hidroclorotiazida PE20120990A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0612540.5A GB0612540D0 (en) 2006-06-23 2006-06-23 Galenical formulations of organic compounds

Publications (1)

Publication Number Publication Date
PE20120990A1 true PE20120990A1 (es) 2012-08-16

Family

ID=36803824

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2007000804A PE20080373A1 (es) 2006-06-23 2007-06-22 Formulaciones de alisquireno e hidroclorotiazida
PE2012000368A PE20120990A1 (es) 2006-06-23 2007-06-22 Formulaciones de alisquireno e hidroclorotiazida

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2007000804A PE20080373A1 (es) 2006-06-23 2007-06-22 Formulaciones de alisquireno e hidroclorotiazida

Country Status (26)

Country Link
US (1) US8618172B2 (es)
EP (3) EP2311439A1 (es)
JP (1) JP5362556B2 (es)
KR (1) KR101442272B1 (es)
CN (1) CN101472566A (es)
AR (1) AR061565A1 (es)
AU (1) AU2007263261B2 (es)
BR (1) BRPI0713338A2 (es)
CA (1) CA2654872A1 (es)
CL (1) CL2007001837A1 (es)
EC (1) ECSP088986A (es)
ES (1) ES2704979T3 (es)
GB (1) GB0612540D0 (es)
GT (1) GT200800297A (es)
IL (1) IL195425A (es)
MA (1) MA30527B1 (es)
MX (1) MX2008016533A (es)
MY (1) MY146779A (es)
NO (1) NO20090262L (es)
NZ (1) NZ572937A (es)
PE (2) PE20080373A1 (es)
RU (1) RU2491058C2 (es)
TN (1) TNSN08528A1 (es)
TW (1) TWI457137B (es)
WO (1) WO2007147596A1 (es)
ZA (1) ZA200809773B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002828A1 (es) * 2007-09-28 2009-05-15 Novartis Ag Tableta oral que comprende una cantidad mayor de 38% de alisquireno o una de sus sales y fosfato acido de calcio como relleno.
EP2143425A1 (de) * 2008-07-11 2010-01-13 Ratiopharm GmbH Direktverpresste Aliskiren-Tabletten
JP2010031006A (ja) * 2008-07-17 2010-02-12 Novartis Ag 有機化合物の使用
ES2365429B1 (es) 2010-03-05 2012-09-06 Universidad De Castilla De La Mancha Solucion para dialisis peritoneal
CN102626391B (zh) * 2012-04-19 2013-07-10 海南美兰史克制药有限公司 一种阿利克仑氢氯噻嗪药物组合物脂质体固体制剂
EP2968182B8 (en) * 2013-03-15 2018-07-25 SpecGx LLC Abuse deterrent solid dosage form for immediate release with functional score

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
TW442301B (en) * 1995-06-07 2001-06-23 Sanofi Synthelabo Pharmaceutical compositions containing irbesartan
TW506836B (en) * 1996-06-14 2002-10-21 Janssen Pharmaceutica Nv Fast-dissolving galanthamine hydrobromide tablet
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6010719A (en) * 1997-09-16 2000-01-04 Universiteit Gent Freeze-dried disintegrating tablets
PE20001302A1 (es) 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
IS1935B (is) * 2002-03-19 2004-06-16 Actavis Group Hf. Fósínópríl lyfjasamsetning
PL219032B1 (pl) * 2002-05-17 2015-03-31 Novartis Ag Kompozycja farmaceutyczna zawierająca alskiren, amlodypinę i hydrochlortiazyd, kombinacja zawierająca te składniki, zastosowanie wspomnianej kombinacji oraz zestaw handlowy zawierający wspomnianą kombinację
BG65538B1 (bg) * 2002-07-05 2008-11-28 "Софарма" Ад Лекарствена форма на силимарин и метод за нейнотополучаване
AR047880A1 (es) * 2004-02-17 2006-03-01 Novartis Ag COMBINACIoN DE UN INHIBIDOR DE RENINA Y DIURÉTICOS
PE20142101A1 (es) 2004-03-17 2014-12-27 Novartis Ag Composiciones farmaceuticas de aliskiren
ATE493973T1 (de) * 2004-06-04 2011-01-15 Teva Pharma Irbesartan enthaltende pharmazeutische zusammensetzung
WO2006041763A1 (en) 2004-10-04 2006-04-20 Novartis Ag Renin inhibitors for treating transplantation induced diseases
US8367105B2 (en) * 2004-11-10 2013-02-05 Teva Pharmaceutical Industries, Ltd. Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
MY146830A (en) 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
BRPI0609915A2 (pt) * 2005-04-27 2010-05-25 Novartis Ag métodos para tratar aterosclerose
AU2006304836A1 (en) * 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent

Also Published As

Publication number Publication date
GB0612540D0 (en) 2006-08-02
JP5362556B2 (ja) 2013-12-11
GT200800297A (es) 2009-03-09
US20090203679A1 (en) 2009-08-13
CL2007001837A1 (es) 2008-06-13
CN101472566A (zh) 2009-07-01
ES2704979T3 (es) 2019-03-21
AU2007263261B2 (en) 2011-07-14
TW200808358A (en) 2008-02-16
IL195425A0 (en) 2009-08-03
MA30527B1 (fr) 2009-06-01
MX2008016533A (es) 2009-01-19
EP3391878A1 (en) 2018-10-24
BRPI0713338A2 (pt) 2012-03-06
PE20080373A1 (es) 2008-06-06
JP2009541239A (ja) 2009-11-26
RU2491058C2 (ru) 2013-08-27
TWI457137B (zh) 2014-10-21
KR20090021353A (ko) 2009-03-03
EP2034968A1 (en) 2009-03-18
EP2311439A1 (en) 2011-04-20
EP2034968B1 (en) 2018-10-31
RU2009101971A (ru) 2010-07-27
WO2007147596A1 (en) 2007-12-27
ZA200809773B (en) 2009-11-25
MY146779A (en) 2012-09-28
CA2654872A1 (en) 2007-12-27
ECSP088986A (es) 2009-01-30
NZ572937A (en) 2011-11-25
US8618172B2 (en) 2013-12-31
AU2007263261A1 (en) 2007-12-27
NO20090262L (no) 2009-01-19
KR101442272B1 (ko) 2014-09-22
AR061565A1 (es) 2008-09-03
TNSN08528A1 (en) 2010-04-14
IL195425A (en) 2014-01-30

Similar Documents

Publication Publication Date Title
ECSP088240A (es) Composición de trazodona para administración una vez por día
PE20120990A1 (es) Formulaciones de alisquireno e hidroclorotiazida
HN2005000795A (es) Pirimidinas como antagonistas del receptor de prostaglandina d2
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
MY177741A (en) Pharmaceutical compositions compring 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one-lactate monohydrate.
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
PE20080698A1 (es) Composiciones farmaceuticas de inhibidores de dpp iv
BRPI0922796A2 (pt) Comprimido farmacêutico para administração por via oral e método de fabricação do mesmo
PE20081374A1 (es) Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
NO341679B1 (no) Substituerte pyridylamidforbindelser, fremstilling av slike og farmasøytiske sammensetninger inneholdende slike, samt anvendelse som modulatorer av histamin H3-reseptoren
CO6150126A2 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina
CY1110097T1 (el) Διπλοστοιβαδικο δισκιο για προληψη καρδιαγγειακων συμβαντων
BR112012009857A8 (pt) Composições farmacêuticas sólidas contendo um inibidor de integrase
MA29278B1 (fr) Composition pharmaceutique comprenant un derive de l'indolylmaleimide
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
UA109627C2 (uk) Композиції тетрациклінових сполук для орального введення та ін'єкцій
PE20090371A1 (es) Formulacion de nevirapina de liberacion prolongada
CY1115955T1 (el) Ενα στερεο φαρμακευτικο σκευασμα
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
WO2007009691A3 (en) Combination of substituted pyrazolines and anti -addictive agent
EA201170913A1 (ru) Фармацевтические составы олмесартана
ATE533477T1 (de) Pharmazeutische zusammensetzungen enthaltend irbesartan
ATE530172T1 (de) Pharmazeutische formulierungen mit clopidogrel
ATE474558T1 (de) Pharmazeutische formulierungen mit irbesartan
ATE357220T1 (de) Pharmazeutische zusammensetzung mit modifizierter freisetzung

Legal Events

Date Code Title Description
FC Refusal